BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company developing antibacterial products for multi-drug resistant infections, announced that all proposals by its Board of Directors were approved by shareholders at the Annual General Meeting held on April 30, 2026.
Shareholders voted in favor of the 2025 Annual Report, financial statements, and the re-election of Seng Chin Mah as Chairman, along with board members David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Simona Skerjanec was elected as a new member of the Board of Directors, replacing Dr. William Jenkins, who stepped down. The maximum compensation for the board until the 2027 AGM and for the executive committee for fiscal year 2027 was also approved.
Chairman Seng Chin Mah expressed gratitude for shareholder trust and highlighted the company's focus on the global Phase 3 trial for BV100, a treatment for Acinetobacter baumannii infections, and progress on alpibectir for tuberculosis in collaboration with GSK. The company aims to address the high unmet need for new antibiotics against resistant bacteria.
BioVersys leverages two platforms—TRIC and Ansamycin Chemistry—to develop candidates that overcome resistance mechanisms. Its pipeline includes BV100 in Phase 3, alpibectir in Phase 2, and preclinical programs. The approval of board proposals ensures continuity in leadership as the company advances its clinical trials.
For investors and industry observers, the unanimous shareholder support signals confidence in BioVersys' strategy and execution. The progress of BV100 and alpibectir could have significant implications for treating life-threatening infections, potentially impacting global health and the antimicrobial resistance crisis.
Detailed meeting documents are available on the company's website: Annual Report and AGM details.
